Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00812058 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression
A Phase 2 study, sponsored by Repligen Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00812058: Completed Phase 2 study, sponsored by Repligen Corporation.
NCT00812058 is a Phase 2 study that has completed, run by Repligen Corporation. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00812058, a Phase 2 study, has completed, sponsored by Repligen Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.
Interventions
- DRUG Placebo
- DRUG RG2417
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00812058 record still lists
NCT00812058 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00812058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00812058 about?
NCT00812058 is a clinical study titled "A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression". The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.
What is the current status of trial NCT00812058?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2008-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00812058?
The interventions under investigation include: Placebo (DRUG), RG2417 (DRUG).
Who is sponsoring clinical trial NCT00812058?
This trial is sponsored by Repligen Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00812058's enrollment target sits among peer trials
180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia